Floatz logo

Humanized Cd19 Car-T Cells

B Lymphoblastic Leukemia/Lymphoma

Zhujiang HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

140 Active assets in the B Lymphoblastic Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Humanized Cd19 Car-T Cells is also rated in:

B-cell non-Hodgkin lymphomaDormant
C
Indicative ·
39 / 100
View asset →
acute lymphoblastic leukemiaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →